Effect of a shortened-duration Eptifibatide infusion (75 mg) as adjunctive therapy for percutaneous coronary intervention on in-hospital cardiovascular outcomes and bleeding Journal Article


Authors: Nei, S. D.; Armon, J. J.; Dierkhising, R. A.; Bell, M. R.; Mathew, V; Barsness, G. W.; Ou, N. N.
Article Title: Effect of a shortened-duration Eptifibatide infusion (75 mg) as adjunctive therapy for percutaneous coronary intervention on in-hospital cardiovascular outcomes and bleeding
Abstract: A retrospective cohort analysis was conducted on patients who underwent percutaneous coronary intervention (PCI) before and after a practice change which reduced the infusion duration of eptifibatide from 18 hours to the time required for completion of a single vial of 75 mg initiated during PCI. Primary end points were inhospital cardiovascular events, target vessel revascularization, and major or minor bleeding. The secondary end point was drug cost. A total of 1,647 patients received the standard-duration infusion (18 hours), and 1,237 received the short-duration infusion. The median infusion times were 18.1 hours (interquartile range 17.7 to 18.7) and 6.6 hours (interquartile range 5.6 to 11.3) in the standard- and short-duration groups, respectively. No differences were found for the rate of inhospital cardiovascular events (2.0% vs 1.9%, respectively; p = 0.78) or inhospital revascularization (0.2% vs 0.3%, respectively; p = 0.68). Also, no statistically significant difference was observed in major bleeding (standard 4.3% vs short 4.4%; p = 0.94) or minor bleeding (standard 3.3% vs short 2.3%; p = 0.09). In conclusion, using a shortened infusion reduced eptifibatide use by an average of 1.6 vials at cost savings of $823 per patient and resulted in no difference in inhospital cardiovascular events, revascularization, or bleeding.
Journal Title: The American Journal of Cardiology
Volume: 115
Issue: 6
ISSN: 1879-1913; 0002-9149
Publisher: Unknown  
Journal Place: United States
Date Published: 2015
Start Page: 707
End Page: 710
Language: eng
DOI/URL:
Notes: LR: 20161125; CI: Copyright (c) 2015; JID: 0207277; 0 (Peptides); 0 (Platelet Aggregation Inhibitors); NA8320J834 (eptifibatide); 2014/09/22 [received]; 2014/12/19 [revised]; 2014/12/19 [accepted]; ppublish